GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Cost of Goods Sold

Pharmala Biotech Holdings (XCNQ:MDMA) Cost of Goods Sold : C$0.37 Mil (TTM As of Feb. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Cost of Goods Sold?

Pharmala Biotech Holdings's cost of goods sold for the three months ended in Feb. 2024 was C$0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.37 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Pharmala Biotech Holdings's Gross Margin % for the three months ended in Feb. 2024 was 100%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Pharmala Biotech Holdings's Inventory Turnover for the three months ended in Feb. 2024 was 0.00.


Pharmala Biotech Holdings Cost of Goods Sold Historical Data

The historical data trend for Pharmala Biotech Holdings's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Cost of Goods Sold Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23
Cost of Goods Sold
- - 0.08

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.08 0.29 -

Pharmala Biotech Holdings Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmala Biotech Holdings  (XCNQ:MDMA) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Pharmala Biotech Holdings's Gross Margin % for the three months ended in Feb. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(0.09 - 0) / 0.09
=100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Pharmala Biotech Holdings's Inventory Turnover for the three months ended in Feb. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Pharmala Biotech Holdings Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.
Executives
Perry Tsergas Director
Shane H.d. Morris Director, Senior Officer
Nicholas Kadysh Director, Senior Officer
Fraser Macdonald Director

Pharmala Biotech Holdings Headlines

No Headlines